RTOG-85-01

Regimen

Experimental
cisplatin/5-FU + 50 Gy RT (combined modality)
Control
64 Gy RT alone

Population

Localized thoracic esophageal carcinoma (squamous or adenocarcinoma)

Key finding

Median OS 12.5 vs 8.9 mo; 2y OS 38% vs 10% (P<0.001) for CRT (cisplatin/5-FU + 50 Gy) vs RT-alone (64 Gy). Established definitive chemoradiotherapy as a curative option.

Source: PMID 1584260

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.53)